Drug shortage
Amphetamine Aspartate Monohydrate · Sandoz Inc.
FDA drug shortage · Current · updated Apr 16, 2025
Key facts
| Generic name | Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet |
|---|---|
| Proprietary name | Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate |
| Company | Sandoz Inc. |
| Presentation | Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0185-2098-01) |
| Dosage form | Tablet |
| Strength | 1.25 mg |
| Status | Current |
| Reason for shortage | Regulatory delay |
| Therapeutic category | Psychiatry |
| Package NDCs | 0185-2098-01 |
| First posted | Oct 12, 2022 |
| Last updated | Apr 16, 2025 |
At a glance
- 1–9 Package NDCs affected
- 100–999 FDA shortage records for this drug
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA drug shortages
The FDA Drug Shortages Database lists current and resolved shortages of drugs, with presentations, affected NDCs and reasons reported by manufacturers.
Source: U.S. Food and Drug Administration (FDA), Drug Shortages Database · Source date: